1.. Introduction
================

In the 1920s, Warburg observed that cancer cells had a distinct metabolism that was highly dependent on glycolysis instead of mitochondrial oxidative phosphorylation, regardless of oxygen availability ([@b1-ol-0-0-4168]). This process was termed the Warburg effect, or aerobic glycolysis ([@b2-ol-0-0-4168]). Hanahan and Weinberg ([@b3-ol-0-0-4168]) also revealed that reprogramming energy metabolism was one of the most common characteristics of cancer cells. Compared with oxidative phosphorylation, glycolysis is a less efficient pathway for producing adenosine triphosphate (ATP) ([@b4-ol-0-0-4168]). To compensate for the loss of ATP due to preferential glycolysis, cancer cells upregulate genes that encode glucose transporters and glycolytic enzymes, which leads to glucose uptake and an altered metabolism ([@b5-ol-0-0-4168]). Increased glucose uptake is used in the clinic for the detection of tumors using fluorodeoxyglucose positron emission tomography ([@b4-ol-0-0-4168]). The metabolic reprogramming of cancer cells provides ATP and allows cells to survive under hypoxic conditions ([@b6-ol-0-0-4168]). In addition, metabolic reprogramming provides cells with biosynthetic building blocks, including intermediates and substrates for the synthesis of nucleotides, proteins and membrane components, which are required in proliferating cells ([@b7-ol-0-0-4168]).

Pyruvate kinase (PK) is a rate-limiting glycolytic enzyme that catalyzes the irreversible transphosphorylation between phosphoenolpyruvate (PEP) and adenosine diphosphate, which produces pyruvate and ATP ([@b8-ol-0-0-4168]). This reaction is a committed step that leads to glycolysis or oxidative phosphorylation of pyruvate ([Fig. 1](#f1-ol-0-0-4168){ref-type="fig"}). In mammals, the PK family consists of four isoforms: liver-type PK (PKL); red blood cell PK (PKR); and PK muscle isozyme M1 and M2 (PKM1 and PKM2, respectively). These isoforms are encoded by two genes, PK, liver and red blood cell (PKLR) and PK, muscle (PKM) ([@b9-ol-0-0-4168],[@b10-ol-0-0-4168]). The expression of pyruvates is tissue-specific and regulated by various promoters and alternative splicing. PKL and PKR are products of the PKLR gene. PKL is expressed in the liver, kidneys and intestine and has the lowest affinity to PEP of the isoforms, while PKR is expressed in red blood cells, inhibited by ATP and activated by fructose-1,6-bisphosphate (FBP). PKM1 and PKM2 are produced by alternative splicing of the primary RNA transcript of the PKM gene, which contains sequences encoded by exons 9 and 10, respectively. The non-allosteric isoform PKM1 is constitutively active, and expressed in terminally differentiated tissues, including the muscle and brain, which require a large supply of ATP. By contrast, PKM2 is expressed in tissues with anabolic functions, including proliferating cells and cancer cells, and is subject to complex allosteric regulation. In the majority of cancer cells, the expression of PKM2 is increased, which suggests that PKM2 may be an attractive target for cancer therapy ([@b11-ol-0-0-4168]). The identification of a novel protein that interacts with PKM2 has confirmed the key function of PKM2 in tumor metabolism and cancer growth ([@b12-ol-0-0-4168]), revealing novel functions of PKM2 beyond the classical concept of glycolysis.

2.. The PKM2 gene and its regulation
====================================

The PKM2 gene is expressed by alternative splicing of PKM pre-messenger (m)RNA ([@b13-ol-0-0-4168]). In cancer cells, PKM2 is overexpressed, and overexpression is controlled by the oncoprotein c-Myc. c-Myc activates the transcription of heterogeneous nuclear ribonucleoproteins (hnRNPs) I, A1 and A2, which bind and repress exon 9 encoding RNA sequences ([@b13-ol-0-0-4168]). This results in the inhibition of PKM1 mRNA splicing, which allows the synchronous expression of the PKM2 isoform ([@b13-ol-0-0-4168]). A previous study demonstrated that PKM was regulated by the reciprocal effects of the mutually exclusive exons 9 and 10, which lead to the repression of exon 9 and the activation of exon 10 in cancer cells ([@b14-ol-0-0-4168]). In addition, knockdown of the serine/arginine-rich family of pre-mRNA splicing factor, which reduces lactate production, triggers the expression of exon 10 and promotes the proliferation of cells and aerobic glycolysis. This study suggested that the exonic elements are the actual determinants of PKM2 splicing, as opposed to classical intronic regions.

In the last decade, studies have focused on the metabolism and signal transduction of cells, and have revealed that oncogenes may have direct or indirect associations with metabolic reprogramming ([@b15-ol-0-0-4168],[@b16-ol-0-0-4168]). Mammalian target of rapamycin (mTOR) was demonstrated to be a key activator of the Warbug effect, as it induces PKM2 and other glycolytic enzymes under normoxic conditions ([@b17-ol-0-0-4168]). Sun *et al* ([@b17-ol-0-0-4168]) demonstrated that PKM2 was a crucial glycolytic enzyme in the oncogenic mTOR-induced Warbug effect, in which hypoxia inducible factor-1α (HIF-1α) and c-Myc-hnRNP cascades are the transducers of mTOR regulation of PKM2. Additionally, insulin is closely associated with cancer progression, and also upregulates PKM2 expression through phosphatidylinositide 3-kinase/mTOR mediated HIF-1α induction ([@b18-ol-0-0-4168]). Notably, the reduction in the activity of PKM2 is independent of this pathway; insulin-induced reactive oxygen species (ROS) was revealed to be responsible ([@b18-ol-0-0-4168]). Under hypoxic conditions, the PKM2 gene interacts directly with HIF-1α, which activates the hypoxia response element that is required for HIF-1α binding ([@b19-ol-0-0-4168]).

A previous study demonstrated that the transcription of PKM2 was upregulated by the epidermal growth factor receptor (EGFR) under normoxic conditions ([@b20-ol-0-0-4168]). EGFR activation induces phospholipase C γ1-dependent protein kinase C (PKC)ε monoubiquitination at lysine-321, which is mediated by RING-finger protein that interacts with C kinase 1 ([@b21-ol-0-0-4168],[@b22-ol-0-0-4168]). Monoubiquitinated PKCε interacts with an ubiquitin-binding domain in the zinc ﬁnger domain of IκB kinase (IKK)γ, which leads to the recruitment of cytosolic IKK to the plasma membrane. PKCε phosphorylates IKKβ at serine-177, which activates IKKβ. Activated v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA) interacts with HIF-1α, which is required for the PKM promoter to bind to RelA ([@b21-ol-0-0-4168],[@b22-ol-0-0-4168]). EGFR-promoted glycolysis and tumorigenesis requires PKCε- and nuclear factor κ enhancer binding protein (NFκB)-dependent PKM2 upregulation ([@b21-ol-0-0-4168],[@b22-ol-0-0-4168]). These molecular interactions reveal the importance of the association between EGFR and NFκB pathways in the upregulation of PKM2 and tumorigenesis of cells.

3.. Active and inactive oligomeric forms of PKM2: Activity regulation
=====================================================================

Cells have evolved complex regulatory mechanisms to adapt the metabolism to various physiological states. Rapidly growing cells consume nutrients at a high rate and must maintain a balance between the utilization of nutrients for ATP synthesis and anabolic development, including protein, lipid and nucleic acid synthesis. Cancer cells use glucose at higher rates compared to non-cancerous cells, but use a smaller fraction for oxidative phosphorylation, which enables cancer cells to incorporate a greater fraction of glucose metabolites in macromolecule synthesis instead of expending it on carbon dioxide production ([@b2-ol-0-0-4168],[@b3-ol-0-0-4168]). Consequently, metabolic programming of cancer cells is required to be flexible, which allows the cells to adapt to various environmental conditions. PKM2 is responsible for the final step of glycolysis and is key in this process ([@b2-ol-0-0-4168],[@b3-ol-0-0-4168]). The preferential expression and allosteric enzymatic activity of PKM2 provides the cancer cells with a growth advantage *in vivo*, without the accumulation of ROS.

Allosteric regulation of PKM2 allows switching between a high- and low-activity state. PKM2 exists in the catalytically distinct tetrameric and dimeric states ([@b2-ol-0-0-4168],[@b3-ol-0-0-4168]). Tetrameric PKM2 exhibits high catalytic activity, which is associated with ATP synthesis and catabolic metabolism in cells. Dimeric PKM2 has low catalytic activity and is the less active state of PKM2 that facilitates the production of glycolytic intermediates to enter the glycolysis branch pathways, including glycerol synthesis and the pentose phosphate pathway, which produces nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) to suppress ROS production and is involved in nucleotide synthesis ([@b2-ol-0-0-4168],[@b3-ol-0-0-4168]).

Various factors have been reported that control the alteration between the dimer and tetramer of PKM2 ([Fig. 2](#f2-ol-0-0-4168){ref-type="fig"}) ([@b23-ol-0-0-4168]). FBP is an upstream glycolytic intermediate and is a well-characterized activator of PKM2, which binds allosterically to PKM2 and facilitates the formation of the active tetramer ([@b11-ol-0-0-4168]). In addition, serine, which is a glycolytic intermediate 3-phosphoglycerate, is a positive regulator of PKM2 ([@b24-ol-0-0-4168]). Serine binds and activates PKM2, and a decrease in serine leads to a reduction in the PKM2 activity in cells ([@b24-ol-0-0-4168]). Phosphoribosylaminoimidazolesuccinocarboxamide (SAICAR) is an intermediate of the *de novo* purine nucleotide synthesis pathway and also stimulates PKM2 activity ([@b25-ol-0-0-4168]). SAICAR-PKM2 interaction promotes cancer cell survival in glucose-limited conditions ([@b25-ol-0-0-4168]--[@b27-ol-0-0-4168]). This allosteric regulation may lead to cancer cells coordinating various metabolic pathways to optimize cell growth in nutrient-limited conditions. PKM2 activity is also regulated by post-translational modifications, including phosphorylation, acetylation and oxidation, which favor the inactive dimeric state of PKM2 ([@b25-ol-0-0-4168]--[@b27-ol-0-0-4168]). Phosphorylation of PKM2 at tyrosine-105 induces the release of FBP, which causes PKM2 to alter between the tetrameric and dimeric states. Additionally, acetylation of PKM2 at lysine-305 downregulates PKM2 activity, which promotes glycolytic pooling, NADPH synthesis and tumor growth ([@b25-ol-0-0-4168]--[@b27-ol-0-0-4168]). Notably, a high glucose concentration induces a lysine-305 acetylation of PKM2, which diverts glucose to anabolic synthesis. Oxidation of PKM2 at cysteine-358 confers an advantage to cancer cells, as it allows the cells to withstand ROS ([@b28-ol-0-0-4168]). Intracellular ROS-induced oxidation of cysteine-358 decreases the activity of PKM2, which diverts glucose flux to the anabolic pentose phosphate pathway, thereby producing sufficient reducing potential for the detoxification of ROS.

Missense mutations in the PKM2 gene, including H391Y and K422R, are observed within the inter-subunit contact domain of the PKM2 protein, which may promote cancer metabolism, oxidative endurance, anchorage independence and tumor growth in a dominant-negative manner ([@b29-ol-0-0-4168]). The two gene mutations have different effects on the activity of PKM2, which does not affect the stability or expression level of the PKM2 protein. The H391Y mutated isoform of PKM2, resulting from a signal amino acid residue replacement, leads to the total loss of allosteric behavior, which affects the dynamic movement of the protein and results in cell rigidity ([@b29-ol-0-0-4168]).

4.. Non-metabolic functions of PKM2
===================================

### PKM2 acts as a coactivator

PKM2 is not only present in the cytoplasm of cells as a PK enzyme, but also translocates to the nucleus, which suggests PKM2 has functions in addition to glycolysis ([@b19-ol-0-0-4168],[@b30-ol-0-0-4168]). There has been a resurgence of interest in the metabolic effects of PKM2, and there have been recent studies revealing non-metabolic functions of PKM2. It has been reported that PKM2 translocates into the nucleus and interacts directly with the HIF-1α subunit and promotes transactivation of HIF-1 target genes by enhancing HIF-1 binding and recruitment of p300, a transcriptional coactivator, which regulates HIF-1 activity ([@b19-ol-0-0-4168],[@b30-ol-0-0-4168]). PKM2 gene transcription is also activated by HIF-1, which creates a positive feedback loop that promotes HIF-1 transactivation and alters glucose metabolism in cancer cells ([@b19-ol-0-0-4168]). The Jumonji C domain-containing dioxygenase Jumonji domain-containing protein 5 (JMJD5) directly interacts with PKM2, which induces the translocation of PKM2 into the nucleus and promotes HIF-1α mediated transactivation ([@b31-ol-0-0-4168]). The JMJD5-PKM2 interaction occurs at the intersubunit interface region of PKM2, which hinders PKM2 tetramerization and blocks PK activity.

The translocation of PKM2, and not PKM1, may be in response to EGFR activation ([@b32-ol-0-0-4168]). In PKM2, lysine-433 binds to c-Src-phosphorylated tyrosine-333 on β-catenin, and this interaction is required for the two proteins to be recruited to the cyclin D1 (CCND1) promoter ([@b32-ol-0-0-4168]). This results in the removal of histone deacetylase 3 (HDAC3) from the promoter, histone H3 acetylation and CCND1 expression ([@b12-ol-0-0-4168]). PKM2-dependent β-catenin transactivation is required for EGFR-promoted tumor cell proliferation and brain tumor development ([@b33-ol-0-0-4168]). In addition, associations have been identified between c-Src activity, β-catenin tyrosine-333 phosphorylation and PKM2 nuclear accumulation in human glioblastoma specimens ([@b32-ol-0-0-4168]). In colorectal cancer, decrease in the expression of PKM2 stimulates the β-catenin signaling pathway, which leads to the promotion of c-Myc-mediated glutamine metabolism ([@b34-ol-0-0-4168]). PKM2 may also be acetylated by p300 acetyltransferase at lysine-433, which prevents PKM2 activation by altering FBP ([@b35-ol-0-0-4168]). Activation of PKM2 promotes the nuclear accumulation and protein kinase activity, which is increased by cell cycle stimulation, EGF and oncoprotein E7. Phosphorylation of PKM2 at serine-37 promotes the translocation of PKM2 to the nucleus through the mitogen-activated protein kinase 1 ERK2 docking groove, which binds directly to PKM2 at isoleucine-429/leucine-431, and the protein kinase activity of PKM2 ([@b36-ol-0-0-4168]). Phosphorylation of PKM2 at serine-37 recruits peptidyl-prolyl *cis-trans* isomerase NIMA-interacting 1 for the *cis-trans* isomerization of PKM2 ([@b36-ol-0-0-4168]). In addition, nuclear PKM2 acts as a coactivator of β-catenin to induce the expression of c-Myc. Upregulation of c-Myc expression by PKM2 creates a positive feedback-loop, since c-Myc elevates the transcription of hnRNPs, which contributes to an increase in the PKM2/PKM1 ratio and promotes glycolysis by driving the expression of enzymatic kinases ([@b36-ol-0-0-4168]).

### Protein kinase activity of PKM2

PKM2 not only acts as a coactivator, but may also act as a protein kinase that phosphorylates substrates involved in metabolic reprogramming. Nuclear dimeric PKM2 directly phosphorylates signal transducer and activator of transcription 3 (STAT3), which is activated in response to inflammatory cytokines, including interleukin-6 ([@b37-ol-0-0-4168]). PKM2 uses PEP as a phosphate donor to phosphorylate STAT3 at tyrosine-705, which activates the transcription of mitogen-activated protein kinase kinase 5. The activation of STAT3 in malignant cancer cells is possibly one of the most important molecular signatures for promoting the progression of cancer. PKM2 overexpression facilitates STAT3 nuclear translocation, which regulates the aggressive progression of colorectal cancer ([@b38-ol-0-0-4168]). The functional implications of the study by Yang *et al* ([@b38-ol-0-0-4168]) indicate that PKM2 activates β1-integrin-focal adhesion kinase and snail-2-E-cadherin signaling, and also upregulates the expression of matrix metalloproteinase-2 and 9, which induces cell migration and adhesion. Similarly to STAT3, histone H3 is a substrate for PKM2 kinase activity ([@b39-ol-0-0-4168]). PKM2 directly binds and phosphorylates histone H3 at threonine-11, which leads to the removal of HDAC3 from CCND1 and Myc promoter regions, subsequent to acetylation at lysine-9 and gene transcription ([@b39-ol-0-0-4168]). PKM2-dependent histone H3 modifications are key to EGF stimulation ([@b19-ol-0-0-4168]). Furthermore, nuclear PKM2 levels are associated with phosphorylation at proline-3/threonine-11 in malignant glioma ([@b36-ol-0-0-4168]). Recently, a study reported that the PKM2-SAICAR interaction is required and sufficient to induce robust protein kinase activity in PKM2 *in vitro* and in cancer cells ([@b26-ol-0-0-4168]). It was also reported that the PKM2-SAICAR complex phosphorylates \>100 human proteins, the majority of which were previously unrecognized. In particular, PKM2-SAICAR directly activates ERK1 *in vitro*; however, activated ERK1/2 phosphorylates PKM2, creating a positive feedback loop ([@b36-ol-0-0-4168]). Additionally, when EGFR is activated, the concentration of cellular SAICAR is increased, which is required to sustain the activation of ERK1/2 and proliferative signaling via PKM2 ([@b36-ol-0-0-4168]).

### PKM2 acts as a differentiating agent

PKM2 acts as a proliferative agent through its interaction with nuclear proteins, and as a differentiating agent through its interaction with octamer-binding transcription factor 4 (Oct4), which is a key regulator in cancer stem cell self-renewal and differentiation ([@b40-ol-0-0-4168]). In glioma stem cells, the interaction between PKM2 and Oct4 inhibits the ability of PKM2 to maintain cell stemness, thereby promoting cell differentiation and enhancing the sensitivity of cells to cell death, which is concomitant with an alteration between the dimer and tetramer states of PKM2 ([@b40-ol-0-0-4168]). Notably, dichloroacetate, which is known as an inhibitor of PDK1 and is involved in the mitochondrial tricarboxylic acid cycle, increases the number of PKM2/Oct4 complexes ([@b41-ol-0-0-4168]).

### PKM2 emergence in blood circulation

PKM2 detected in the blood of patients with gastrointestinal, pancreatic, lung and ovarian cancer and renal cell carcinoma revealed that PKM2 is released into the circulation ([@b42-ol-0-0-4168]). The PKM2 levels in the circulation of patients may be used as a diagnostic marker for numerous types of cancer ([@b43-ol-0-0-4168]). A recent study suggested that PKM2 in the blood circulation facilitated tumor growth by promoting tumor angiogenesis ([@b44-ol-0-0-4168]). The study demonstrated that PKM2 promoted tumor angiogenesis by increasing endothelial cell proliferation, migration and extracellular matrix-cell adhesions; only dimeric PKM2 was observed to be involved in tumor angiogenesis.

5.. PKM2 as a therapeutic target
================================

Cancer-specific metabolism, which is closely associated with tumorigenicity, cancer aggressive progression and inherent or acquired therapeutic resistance, is an attractive target for cancer therapy. The role of PKM2 in glycolysis and the proliferation of cancer cells has been revealed, and has been demonstrated to balance the production of biomolecular building blocks and the generation of pyruvate and ATP. Consequently, there are two therapeutic strategies for targeting PKM2. The first is inhibitors that block the catalytic activity of PKM2, and the second is activators that induce tetramerization of PKM2 to increase glycolysis.

### Inhibition of PMK2 activity

Inhibitors of PKM2 appear to rely on the hypothesis that proliferating cells are highly dependent on energy, and a reduced activity of PKM2 inhibits energy regeneration. Using a high throughput screen, small molecules have been identified that selectively inhibit PKM2 ([@b45-ol-0-0-4168]). These molecules target the allosteric FBP binding site of PKM2; however, since PKL and PKR are also activated by FBP, there may be toxicity issues for human cancer therapy if PK activity is inhibited in the liver and red blood cells. Natural products, such as shikonin and its analog alkannin, which belong to a family of necroptotic inducers, demonstrated potent and promising selective inhibition of PKM2 that did not inhibit PKM1 and PKL ([@b46-ol-0-0-4168]). However, PKM2 inhibition by these drugs is partially reversed by the addition of FBP to protein lysates.

RNA interference targeting PKM2 has been observed to attenuate growth and induce caspase-dependent apoptosis in several cancer cell lines ([@b47-ol-0-0-4168]). In addition, peptide aptamers, which inhibit PKM2 and not the homologous PKM1, induce a significant decrease in cell proliferation and size under conditions where glucose metabolism is disrupted ([@b48-ol-0-0-4168]).

Although the inhibition of PKM2 has been demonstrated to be successful against cancer cell proliferation, the majority of cells are characterized by a high glutaminolysis capacity, which is another source of energy ([@b47-ol-0-0-4168]). Therefore, an inhibition of PKM2 may not be sufficient to significantly reduce the cellular proliferation of tumor cells.

### Activators of PKM2

PKM2 activators aim to induce tetramerization of PKM2, which results in a decrease in glycolytic intermediates that are used as biosynthetic precursors. A class of quinolone sulfonamide activators has been reported to possess a distinctive mode of binding to PKM2 ([@b49-ol-0-0-4168]). These activators bind to a site that is distinct from the FBP binding site, which results in the diversion of glycolytic intermediates away from the serine biosynthetic pathway, which produces serine that is required for continued cell proliferation. A library of 13,000,000 drug-like compounds was screened *in silico* against the PKM2 structure, and 9 novel scaffolds were identified as PKM2 activators ([@b50-ol-0-0-4168]). These molecules had low nanomolar PKM2 potency, with excellent selectivity to other PK isoforms and good absorption, distribution, metabolism and excretion properties. A series of pyridopyrimidine analogs were also reported as potent activators of PKM2, with good stability, permeability, solubility and selectivity to PKM2 ([@b51-ol-0-0-4168]). However, PKM2 activation alone is not sufficient to alter cancer cell metabolism. Another series of small molecule PKM2 activators did not affect the growth of cancer cell lines under normal conditions *in vitro*, but strongly inhibited the proliferation of multiple lung cancer cell lines when serine was removed from the cell culture media ([@b52-ol-0-0-4168]). Screening of an in-house fragment-like library of 2,000 other compounds, led to the identification of another series of small molecules, which caused 50% of the cell population to undergo apoptosis at a concentration of 36 µM, with 104% maximal response compared with the natural PKM2 ligand and FBP activator ([@b53-ol-0-0-4168]). All the reported small molecule activators of PKM2 bind to a site that is distinct from the binding site of FBP, which is located on the opposite side of the tetramer interface compared with the FBP site.

By contrast, oleanolic acid (OA) did not interact with PKM2, which affects the splicing of the PKM gene ([@b54-ol-0-0-4168]). Decreased expression of c-Myc-dependent hnRNA1, a subtype of hnRNPs, and mTOR inhibition were responsible for the OA-induced switch between PKM isoforms.

Overall, there are a number of PKM2 inhibitors and activators that are in preclinical development; however, to date, none have advanced to human clinical studies. The present study suggests that PKM2 activators may be a more promising therapeutic target for patients with cancer compared with PKM2 inhibitors. However, the serine auxotrophy induced by PKM2 activators may be reversed by multiple pathways, including *de novo* serine synthesis, conversion from glycine, catabolism from proteins and serine-containing phospholipids and absorption from the extracellular environment, which may present a challenge when investigating activators.

6.. Conclusion
==============

The present review focused on the PKM2 gene and its regulation, and emphasized the non-metabolic function of PKM2 and the development of PKM2 as a therapeutic target. In the last decade, extensive research has clarified the notable involvement of PKM2 in cancer through its canonical and non-canonical functions. This allosteric property of PKM2 balances cell growth and oxidative stress.

However, PKM2 has multiple roles, and the intracellular mechanisms induced by PKM2 are more complicated than previously hypothesized. Protein kinases are important regulators in numerous biological processes. Numerous human proteins have been identified as potential substrates for PKM2, the majority of which are involved in the regulation of cell proliferation. Additional studies concerning the mechanism of PKM2 substrate recognition may reveal a common mechanism between the proteins involved in cell-cycle regulation. It has been demonstrated that the cell microenvironment provides metabolic heterogeneity in cancer tissues, which may be caused by differences in the supply of nutrients and oxygen ([@b55-ol-0-0-4168]). Cancer cells are located at various distances from blood vessels, in which PKM2 may play a role. Certain studies suggest that overexpression of PKM2 may be a biomarker for specific types of cancer ([@b56-ol-0-0-4168]--[@b58-ol-0-0-4168]); however, this is controversial and additional studies are required for confirmation. The regulation of PKM2 requires additional clarification. Even by providing a functional readout of the oxidative and metabolic state of the cell, it is not fully clear how PKM2 alters the response of the cell to growth factor stimulation ([@b59-ol-0-0-4168]); however, the association between PKM2 and growth factor responses and oxidative stress responses indicates that this regulation is integrated. It is also contradictory that certain studies report that knockdown of PKM2 results in a modest inhibitory effect on *in vitro* proliferation of cancer cells and xenograft tumors without signs of inhibition, which indicates that PKM2 is not a requirement for tumor growth ([@b45-ol-0-0-4168],[@b46-ol-0-0-4168]).

In conclusion, PKM2 is essential in the metabolic reprogramming of cancer cells; however, cancer cells reprogram using several metabolic pathways to support cell growth. An improved understanding of metabolism transformation in early cancer cells and how this results in the development and progression of cancer may provide an understanding of the metabolic and non-metabolic functions of PKM2. Furthermore, targeting PKM2 as a treatment for cancer may significantly evolve over the next several years.
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